SuperworthMyriad Genetics profit margin MYGN
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- −14.0%
- Operating margin, 12 months
- −12.2%
- Net margin on a year earlier
- +33.5 pts
- Peer median
- 9.5%
Over the twelve months to Jun 30, 2026, Myriad Genetics kept −14.0% of its revenue as net profit, with an operating margin of −12.2% and a gross margin of 68.8%.
Five years earlier its net margin was −14.7%.
The median for 5 diagnostics and research stocks of a similar size is 9.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −44.4% | −47.0% | 69.9% |
| FY2024 | −15.2% | −14.7% | 69.9% |
| FY2023 | −35.0% | −34.2% | 68.6% |
| FY2022 | −16.5% | −20.7% | 70.2% |
| FY2021 | −3.9% | −27.6% | 71.4% |
| FY2020 | −31.2% | −36.3% | 70.9% |
| FY2020 | −40.1% | −52.0% | 68.0% |
| FY2019 | 0.5% | 0.9% | 76.4% |
| FY2018 | 17.9% | 16.4% | 76.2% |
| FY2017 | 2.7% | 6.3% | 77.8% |
| FY2016 | 16.6% | 22.1% | 79.1% |
| FY2015 | 11.1% | 18.6% | 79.6% |
| FY2014 | 22.6% | 35.3% | 86.0% |
| FY2013 | 24.0% | 37.2% | 87.0% |
| FY2012 | 22.6% | 36.4% | 87.6% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −14.0% | +33.5 pts | −12.2% | |
| Q1 FY26 | −48.2% | −36.0 pts | −46.9% | |
| Q4 FY25 | −44.4% | −29.2 pts | −47.0% | |
| Q3 FY25 | −48.5% | −34.4 pts | −51.0% | |
| Q2 FY25 | −47.4% | −28.1 pts | −50.1% | |
| Q1 FY25 | −12.2% | +18.1 pts | −15.0% | |
| Q4 FY24 | −15.2% | +19.8 pts | −14.7% | |
| Q3 FY24 | −14.1% | +23.3 pts | −14.1% | |
| Q2 FY24 | −19.3% | +16.2 pts | −19.4% | |
| Q1 FY24 | −30.3% | −9.3 pts | −30.1% | |
| Q4 FY23 | −35.0% | −18.4 pts | −34.2% | |
| Q3 FY23 | −37.4% | −25.7 pts | −37.9% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Myriad Genetics' size, closest first, today.
| Company | Profit margin |
|---|---|
| MYGNMyriad Genetics | −14.0% |
| NRCNRC Health | 4.2% |
| ICCCImmucell | 2.6% |
| CDNACareDx | 24.2% |
| VCYTVeracyte | 20.4% |
| BLLNBillionToOne | 9.5% |
| Peer median | 9.5% |
Where Myriad Genetics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Myriad Genetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.